Maillart et al - NEURIMMINFL/2016/009894 Figure e-1: Legend of the figure e-1 Evolution of brain MRI of patient 1: two (M2), four (M4) and thirty-five (M35) months after Progressive Multifocal Leukoencephalopathy (PML) diagnosis. Modified from figure 1, from Maillart E, et al. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Multiple sclerosis 2014;20:505-509. Fluid-attenuated inversion recovery (FLAIR) (a and e) and T1- weighted sequence with gadolinium (b, c, d, f) • IRIS : FLAIR (a) and T1 weighted-sequence with gadolinium (b): ontrast enhancement surrounding PML lesions. • multiple sclerosis activity: T1-weighted sequence with gadolinium (c, d) • On fingolimod: FLAIR (e) and T1 weighted-sequence with gadolinium (f): no progression of PML lesion, severe atrophy. MS: multiple sclerosis; MRI: magnetic resonance imaging; PML: progressive multifocal leukoencephalopathy; IRIS: immune reconstitution inflammatory syndrome
5
Embed
Neurology: Neuroimmunology & Neuroinflammation · Web view2017/04/14 · MS: multiple sclerosis; MRI: magnetic resonance imaging; PML: progressive multifocal leukoencephalopathy;
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Maillart et al - NEURIMMINFL/2016/009894
Figure e-1:
Legend of the figure e-1
Evolution of brain MRI of patient 1: two (M2), four (M4) and thirty-five (M35) months
after Progressive Multifocal Leukoencephalopathy (PML) diagnosis.
Modified from figure 1, from Maillart E, et al. Fingolimod to treat severe multiple scle-
rosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid
option? Multiple sclerosis 2014;20:505-509.
Fluid-attenuated inversion recovery (FLAIR) (a and e) and T1-weighted sequence with
gadolinium (b, c, d, f)
• IRIS : FLAIR (a) and T1 weighted-sequence with gadolinium (b): ontrast enhancement sur-
rounding PML lesions.
• multiple sclerosis activity: T1-weighted sequence with gadolinium (c, d)
• On fingolimod: FLAIR (e) and T1 weighted-sequence with gadolinium (f): no progression
of PML lesion, severe atrophy.
MS: multiple sclerosis; MRI: magnetic resonance imaging; PML: progressive multifocal